Krystal BiotechFRA:4KB +2.29%58 FCF Margin % is 62.94% as of Mar. 2026, which is 53% above its 10-year median of 41.02. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €263.13 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, Krystal Biotech ranks better than 97.6% on this metric.
The historical rank and industry rank for Krystal Biotech's FCF Margin % or its related term are showing as below:
FRA:4KB'
s FCF Margin % Range Over the Past 10 Years
Min: -198.43 Med: 41.02 Max: 56.9
Current: 56.9
During the past 10 years, the highest FCF Margin % of Krystal Biotech was 56.90%. The lowest was -198.43%. And the median was 41.02%.
FRA:4KB's FCF Margin % is ranked better than 97.6% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs FRA:4KB: 56.90
Krystal Biotech FCF Margin % Related Terms
Krystal Biotech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, PRAX, TECH: FCF Margin % Comparison
For the Biotechnology subindustry, Krystal Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a FCF Margin % of 62.94% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Krystal Biotech and its competitors. This is 53% above median its historical median of 41.02. According to the industry distribution chart, Krystal Biotech ranks #23 out of 959 companies in the Biotechnology industry, placing it in the top 2.4%.
Is Krystal Biotech's FCF Margin % too high?
Krystal Biotech's current FCF Margin % of 62.94% is 53% above median its 10-year median of 41.02. Based on the distribution chart, Krystal Biotech ranks #23 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's FCF Margin % compare to NUVL and PRAX?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #23 out of 959 companies for FCF Margin %. This places Krystal Biotech in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current FCF Margin % is 62.94%, which is 53% above median its own 10-year median of 41.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €263.13, compared to a current price of €303.60 — trading 15.4% above its estimated fair value. The current FCF Margin % is 62.94%, which is 53% above median its 10-year median of 41.02. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current FCF Margin % is 62.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €303.60 is trading 15.4% above its estimated GF Value™ of €263.13.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
FCF Margin %: 62.94% (53% above median its 10-year median of 41.02)
GF Value™: €263.13 vs. price of €303.60 (15.4% above fair value)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
